Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics

– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio –

GlobeNewsWire • May 12, 2026

Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (COLL) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 7, 2026

Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress

– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year –  – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track to Close Acquisition of AZSTARYS ® in Second Quarter of 2026, Adding Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium's Existing ADHD Portfolio – – Generated Quarterly Pain Portfolio Net Revenues of $154.6 Million, Up 4% Year-over-Year – – Ended Q1'26 with Cash, Cash Equivalents and Marketable Securities of $421.8 Million – – Reaffirmed Full-Year 2026 Guidance for the Current Business – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

GlobeNewsWire • May 7, 2026

Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • May 7, 2026

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.76 per share, beating the Zacks Consensus Estimate of $1.42 per share. This compares to earnings of $1.49 per share a year ago.

Zacks Investment Research • May 7, 2026

Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Apr 30, 2026

Collegium to Report First Quarter 2026 Financial Results on May 7, 2026

STOUGHTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026. Following the release of the financials, the Company will host a live conference call and webcast at 8:00 a.m. ET.

GlobeNewsWire • Apr 23, 2026

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Wednesday, April 15, 2026, at 2:15 p.m.

GlobeNewsWire • Apr 8, 2026

Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD

6,224 shares were sold for a transaction value of ~$228,000 on March 9, 2026. This sale represented 6.40% of Dieter David's direct holdings prior to the transaction.

The Motley Fool • Mar 31, 2026

Collegium Pharmaceutical EVP Sells Nearly 50,000 Shares Worth $2 Million

Scott Dreyer sold 49,976 shares on March 3, 2026, for approximately $2.02 million at a weighted average price of about $40.41 per share. The sale reduced Dreyer's direct holdings by 41.05%, from 121,746 shares to 71,770 shares.

The Motley Fool • Mar 25, 2026